Compare VFF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | MGNX |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.2M | 220.6M |
| IPO Year | 2013 | 2013 |
| Metric | VFF | MGNX |
|---|---|---|
| Price | $1.99 | $4.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $215,937,000.00 | $149,500,000.00 |
| Revenue This Year | $12.19 | N/A |
| Revenue Next Year | $15.82 | $3.19 |
| P/E Ratio | $99.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $1.30 |
| 52 Week High | $4.99 | $5.08 |
| Indicator | VFF | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 52.72 |
| Support Level | $1.81 | $1.49 |
| Resistance Level | $2.10 | $4.55 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 61.02 | 46.64 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Cannabis - Netherlands. The company makes majority of its revenue from the Cannabis Canada segment.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.